VIRX Viracta Therapeutics Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Rojkjaer Lisa	2. Issuer Name and Ticker or Trading Symbol Viracta Therapeutics, Inc. [ VIRX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Medical Officer
(Last)          (First)          (Middle) C/O VIRACTA THERAPEUTICS, INC., 2533 S COAST HWY 101, SUITE 210	3. Date of Earliest Transaction (MM/DD/YYYY) 5/11/2021
(Street) CARDIFF, CA 92007 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	5/11/2021		M		32689	A	$1.26	32689	D
Common Stock	5/11/2021		M		2061	A	$3.58	34750	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.26	5/11/2021		M			32689	(1)	7/8/2030	Common Stock	32689	$0.00	98069	D
Stock Option (Right to Buy)	$3.58	5/11/2021		M			2061	(2)	1/8/2031	Common Stock	2061	$0.00	30956	D

Explanation of Responses:
(1)	Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of May 1, 2020 (the "Vesting Commencement Date"), and one forty-eighth (1/48th ) of the total shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through each such date.
(2)	One forty-eighth (1/48th ) of the Shares subject to the Option shall vest on February 28, 2021, and one forty-eighth (1/48th ) of the total Shares subject to the Option shall vest each month thereafter on the last day of such month, subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through each such date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Rojkjaer Lisa C/O VIRACTA THERAPEUTICS, INC. 2533 S COAST HWY 101, SUITE 210 CARDIFF, CA 92007			Chief Medical Officer

Signatures
/s/ Michael Mueller, as Attorney-in-Fact		5/13/2021
**Signature of Reporting Person		Date